{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:33:04Z","timestamp":1790274784556,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T00:00:00Z","timestamp":1530489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31570892"],"award-info":[{"award-number":["31570892"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730045"],"award-info":[{"award-number":["81730045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91527305"],"award-info":[{"award-number":["91527305"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00262-018-2177-1","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T06:00:54Z","timestamp":1530511254000},"page":"1355-1364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells"],"prefix":"10.1007","volume":"67","author":[{"given":"Yuting","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-1111","authenticated-orcid":false,"given":"Yiwei","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,2]]},"reference":[{"issue":"3","key":"2177_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162\u2013174","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2177_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00262-011-1161-9","volume":"61","author":"P Filipazzi","year":"2012","unstructured":"Filipazzi P, Huber V, Rivoltini L (2012) Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 61(2):255\u2013263. \n                    https:\/\/doi.org\/10.1007\/s00262-011-1161-9","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2177_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.immuni.2014.10.020","volume":"41","author":"JM Haverkamp","year":"2014","unstructured":"Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT, Murray PJ (2014) Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity 41(6):947\u2013959. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2014.10.020","journal-title":"Immunity"},{"issue":"5","key":"2177_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674. \n                    https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"2","key":"2177_CR5","doi-asserted-by":"publisher","first-page":"e1004983","DOI":"10.1080\/2162402X.2015.1004983","volume":"5","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Wu T, Shao S, Shi B, Zhao Y (2015) Phenotype, development, and biological function of myeloid-derived suppressor cells. Oncoimmunology 5(2):e1004983. \n                    https:\/\/doi.org\/10.1080\/2162402x.2015.1004983","journal-title":"Oncoimmunology"},{"issue":"3","key":"2177_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","volume":"39","author":"TX Cui","year":"2013","unstructured":"Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, Kotarski J, Tarkowski R, Wicha M, Cho K, Giordano T, Liu R, Zou W (2013) Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 39(3):611\u2013621. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2013.08.025","journal-title":"Immunity"},{"issue":"7","key":"2177_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/cmi.2015.103","volume":"14","author":"X Xu","year":"2017","unstructured":"Xu X, Meng Q, Erben U, Wang P, Glauben R, Kuhl AA, Wu H, Ma CW, Hu M, Wang Y, Sun W, Jia J, Wu X, Chen W, Siegmund B, Qin Z (2017) Myeloid-derived suppressor cells promote B-cell production of IgA in a TNFR2-dependent manner. Cell Mol Immunol 14(7):597\u2013606. \n                    https:\/\/doi.org\/10.1038\/cmi.2015.103","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"2177_CR8","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","volume":"182","author":"S Ostrand-Rosenberg","year":"2009","unstructured":"Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182(8):4499\u20134506. \n                    https:\/\/doi.org\/10.4049\/jimmunol.0802740","journal-title":"J Immunol"},{"key":"2177_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1935-1","author":"HF Wang","year":"2016","unstructured":"Wang HF, Ning F, Liu ZC, Wu L, Li ZQ, Qi YF, Zhang G, Wang HS, Cai SH, Du J (2016) Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro. Cancer Immunol Immunother. \n                    https:\/\/doi.org\/10.1007\/s00262-016-1935-1","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"2177_CR10","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.1158\/0008-5472.CAN-13-0987","volume":"73","author":"A Sawant","year":"2013","unstructured":"Sawant A, Schafer CC, Jin TH, Zmijewski J, Tse HM, Roth J, Sun Z, Siegal GP, Thannickal VJ, Grant SC, Ponnazhagan S, Deshane JS (2013) Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res 73(22):6609\u20136620. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0987","journal-title":"Cancer Res"},{"key":"2177_CR11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2261","author":"D Mitri Di","year":"2015","unstructured":"Di Mitri D, Toso A, Alimonti A (2015) Molecular pathways: targeting tumor-infiltrating myeloid-derived suppressor cells for cancer therapy. Clin Cancer Res. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2261","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2177_CR12","doi-asserted-by":"publisher","first-page":"e1230578","DOI":"10.1080\/2162402X.2016.1230578","volume":"5","author":"T Spinetti","year":"2016","unstructured":"Spinetti T, Spagnuolo L, Mottas I, Secondini C, Treinies M, Ruegg C, Hotz C, Bourquin C (2016) TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function. Oncoimmunology 5(11):e1230578. \n                    https:\/\/doi.org\/10.1080\/2162402X.2016.1230578","journal-title":"Oncoimmunology"},{"issue":"9","key":"2177_CR13","doi-asserted-by":"publisher","first-page":"e1214787","DOI":"10.1080\/2162402X.2016.1214787","volume":"5","author":"P Trikha","year":"2016","unstructured":"Trikha P, Plews RL, Stiff A, Gautam S, Hsu V, Abood D, Wesolowski R, Landi I, Mo X, Phay J, Chen CS, Byrd J, Caligiuri M, Tridandapani S, Carson W (2016) Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Oncoimmunology 5(9):e1214787. \n                    https:\/\/doi.org\/10.1080\/2162402X.2016.1214787","journal-title":"Oncoimmunology"},{"issue":"10","key":"2177_CR14","doi-asserted-by":"publisher","first-page":"e956579","DOI":"10.4161\/21624011.2014.956579","volume":"3","author":"SK Maenhout","year":"2014","unstructured":"Maenhout SK, Thielemans K, Aerts JL (2014) Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells. Oncoimmunology 3(10):e956579. \n                    https:\/\/doi.org\/10.4161\/21624011.2014.956579","journal-title":"Oncoimmunology"},{"issue":"11","key":"2177_CR15","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI (2010) HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207(11):2439\u20132453. \n                    https:\/\/doi.org\/10.1084\/jem.20100587","journal-title":"J Exp Med"},{"issue":"3","key":"2177_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2014.08.015","volume":"41","author":"PT Thevenot","year":"2014","unstructured":"Thevenot PT, Sierra RA, Raber PL, Al-Khami AA, Trillo-Tinoco J, Zarreii P, Ochoa AC, Cui Y, Del Valle L, Rodriguez PC (2014) The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 41(3):389\u2013401. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2014.08.015","journal-title":"Immunity"},{"key":"2177_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fimmu.2014.00387","volume":"5","author":"S Gantt","year":"2014","unstructured":"Gantt S, Gervassi A, Jaspan H, Horton H (2014) The role of myeloid-derived suppressor cells in immune ontogeny. Front Immunol 5:387. \n                    https:\/\/doi.org\/10.3389\/fimmu.2014.00387","journal-title":"Front Immunol"},{"issue":"11","key":"2177_CR18","doi-asserted-by":"publisher","first-page":"e26967","DOI":"10.4161\/onci.26967","volume":"2","author":"D Chandra","year":"2013","unstructured":"Chandra D, Gravekamp C (2013) Myeloid-derived suppressor cells: Cellular missiles to target tumors. Oncoimmunology 2(11):e26967. \n                    https:\/\/doi.org\/10.4161\/onci.26967","journal-title":"Oncoimmunology"},{"key":"2177_CR19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051013-052304","author":"T Condamine","year":"2014","unstructured":"Condamine T, Ramachandran I, Youn JI, Gabrilovich DI (2014) Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med. \n                    https:\/\/doi.org\/10.1146\/annurev-med-051013-052304","journal-title":"Annu Rev Med"},{"issue":"5930","key":"2177_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029\u20131033. \n                    https:\/\/doi.org\/10.1126\/science.1160809","journal-title":"Science"},{"issue":"10","key":"2177_CR21","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1172\/JCI69589","volume":"123","author":"M Sukumar","year":"2013","unstructured":"Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L (2013) Inhibiting glycolytic metabolism enhances CD8 + T cell memory and antitumor function. J Clin Invest 123(10):4479\u20134488. \n                    https:\/\/doi.org\/10.1172\/jci69589","journal-title":"J Clin Invest"},{"issue":"6","key":"2177_CR22","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang C-H, Qiu J, O\u2019Sullivan D, Buck Michael D, Noguchi T, Curtis Jonathan D, Chen Q, Gindin M, Gubin Matthew M, van der Windt Gerritje JW, Tonc E, Schreiber Robert D, Pearce Edward J, Pearce Erika L (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162(6):1229\u20131241. \n                    https:\/\/doi.org\/10.1016\/j.cell.2015.08.016","journal-title":"Cell"},{"issue":"1","key":"2177_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/JOE-12-0356","volume":"216","author":"LM Hinder","year":"2012","unstructured":"Hinder LM, Vivekanandan-Giri A, McLean LL, Pennathur S, Feldman EL (2012) Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes. J Endocrinol 216(1):1\u201311. \n                    https:\/\/doi.org\/10.1530\/joe-12-0356","journal-title":"J Endocrinol"},{"key":"2177_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. \n                    https:\/\/doi.org\/10.1016\/j.it.2016.01.004","journal-title":"Trends Immunol"},{"issue":"2","key":"2177_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274\u2013293. \n                    https:\/\/doi.org\/10.1016\/j.cell.2012.03.017","journal-title":"Cell"},{"issue":"2","key":"2177_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"LE Raez","year":"2013","unstructured":"Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ (2013) A phase dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 71(2):523\u2013530. \n                    https:\/\/doi.org\/10.1007\/s00280-012-2045-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2177_CR27","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bcp.12893","volume":"82","author":"M Waldner","year":"2016","unstructured":"Waldner M, Fantus D, Solari M, Thomson AW (2016) New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. Br J Clin Pharmacol 82(5):1158\u20131170. \n                    https:\/\/doi.org\/10.1111\/bcp.12893","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2177_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5500\/wjt.v6.i1.183","volume":"6","author":"A Baroa-Mazo","year":"2016","unstructured":"Baroa-Mazo A, Revilla-Nuin B, Ramirez P, Pons JA (2016) Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation. World J Transplant 6(1):183\u2013192. \n                    https:\/\/doi.org\/10.5500\/wjt.v6.i1.183","journal-title":"World J Transplant"},{"issue":"1","key":"2177_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","volume":"59","author":"RN Saunders","year":"2001","unstructured":"Saunders RN, Metcalfe MS, Nicholson ML (2001) Rapamycin in transplantation: a review of the evidence. Kidney Int 59(1):3\u201316. \n                    https:\/\/doi.org\/10.1046\/j.1523-1755.2001.00460.x","journal-title":"Kidney Int"},{"issue":"2","key":"2177_CR30","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/ijms13021886","volume":"13","author":"H Populo","year":"2012","unstructured":"Populo H, Lopes JM, Soares P (2012) The mTOR signalling pathway in human cancer. Int J Mol Sci 13(2):1886\u20131918. \n                    https:\/\/doi.org\/10.3390\/ijms13021886","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2177_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","volume":"36","author":"P Wu","year":"2015","unstructured":"Wu P, Nielsen TE, Clausen MH (2015) FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36(7):422\u2013439. \n                    https:\/\/doi.org\/10.1016\/j.tips.2015.04.005","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"2177_CR32","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","volume":"3","author":"F Hossain","year":"2015","unstructured":"Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, Valle LD, Trillo-Tinoco J, Maj T, Zou W, Rodriguez PC, Ochoa AC (2015) Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res 3(11):1236\u20131247. \n                    https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0036","journal-title":"Cancer Immunol Res"},{"key":"2177_CR33","doi-asserted-by":"publisher","first-page":"20250","DOI":"10.1038\/srep20250","volume":"6","author":"T Wu","year":"2016","unstructured":"Wu T, Zhao Y, Wang H, Li Y, Shao L, Wang R, Lu J, Yang Z, Wang J, Zhao Y (2016) mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors. Sci Rep 6:20250. \n                    https:\/\/doi.org\/10.1038\/srep20250","journal-title":"Sci Rep"},{"key":"2177_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2017.1381804","author":"L Jiao","year":"2017","unstructured":"Jiao L, Zhang HL, Li DD, Yang KL, Tang J, Li X, Ji J, Yu Y, Wu RY, Ravichandran S, Liu JJ, Feng GK, Chen MS, Zeng YX, Deng R, Zhu XF (2017) Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2). Autophagy. \n                    https:\/\/doi.org\/10.1080\/15548627.2017.1381804","journal-title":"Autophagy"},{"issue":"3","key":"2177_CR35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.pbi.2004.03.007","volume":"7","author":"AR Fernie","year":"2004","unstructured":"Fernie AR, Carrari F, Sweetlove LJ (2004) Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport. Curr Opin Plant Biol 7(3):254\u2013261. \n                    https:\/\/doi.org\/10.1016\/j.pbi.2004.03.007","journal-title":"Curr Opin Plant Biol"},{"issue":"2","key":"2177_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","volume":"44","author":"V Kumar","year":"2016","unstructured":"Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, Hockstein N, Guarino M, Masters G, Penman E, Denstman F, Xu X, Altieri DC, Du H, Yan C, Gabrilovich DI (2016) CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44(2):303\u2013315. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2016.01.014","journal-title":"Immunity"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2177-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2177-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2177-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T20:36:47Z","timestamp":1568925407000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2177-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,2]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2177"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2177-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,2]]},"assertion":[{"value":"20 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest. 3LL Lewis Lung Carcinoma cells were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences. C57BL\/6 mice were purchased from the Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments were approved by the Institutional Animal Care and Use Committee of Fudan University (20140226067) following the Guidelines for the Care and Use of Laboratory Animals (No. 55 issued by Ministry of Health, China on January 25th, 1998).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal rights"}}]}}